User Tools

Site Tools


algae:pharma_medical

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
algae:pharma_medical [2026-09-13 21:44] – [Food supplement vs. medicinal product] robertalgae:pharma_medical [2026-09-14 00:40] (current) – [Good Manufacturing Practice (GMP)] robert
Line 17: Line 17:
 This means that: This means that:
  
-  * An algal extract sold as a food supplement with claims limited to normal physiological function (e.g. "supports immune health") falls under food supplement law (Directive 2002/46/EC and national rules — see [[algae:food:supplements|Food Supplements]]).+  * An algal extract sold as a food supplement with claims limited to normal physiological function (e.g. "supports immune health") falls under food supplement law (Directive 2002/46/EC [[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02002L0046-20251126|EURlex]] and national rules — see [[algae:food:supplements|Food Supplements]]).
   * The same extract, marketed with claims about treating, curing or preventing a specific disease, or with a pharmacological dose and a demonstration of pharmacological activity, is a medicinal product by presentation or by function, even if the extract itself is identical.   * The same extract, marketed with claims about treating, curing or preventing a specific disease, or with a pharmacological dose and a demonstration of pharmacological activity, is a medicinal product by presentation or by function, even if the extract itself is identical.
   * A product that straddles this line will be classified as a medicinal product under Article 2(2) of Directive 2001/83/EC, which provides that in case of doubt, medicinal products law prevails.   * A product that straddles this line will be classified as a medicinal product under Article 2(2) of Directive 2001/83/EC, which provides that in case of doubt, medicinal products law prevails.
Line 55: Line 55:
 ==== Human Medicines Directive ==== ==== Human Medicines Directive ====
  
-Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02001L0083-20220101|EURlex]].+Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [[https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02001L0083-20250101|EURlex]].
  
 __Relevance to algae:__ This Directive is the principal EU legal framework for medicines. It is relevant to algae in the following contexts: __Relevance to algae:__ This Directive is the principal EU legal framework for medicines. It is relevant to algae in the following contexts:
Line 96: Line 96:
  
 The European Pharmacopoeia establishes quality standards (identity, purity, assay) for pharmaceutical-grade algal materials. Compliance with Ph. Eur. monographs is expected by regulatory authorities and buyers in the pharmaceutical supply chain. The European Pharmacopoeia establishes quality standards (identity, purity, assay) for pharmaceutical-grade algal materials. Compliance with Ph. Eur. monographs is expected by regulatory authorities and buyers in the pharmaceutical supply chain.
 +
 +----
 +
 +=== Forthcoming changes ===
 +
 +Following years of negotiations, the final texts of the new EU Pharma Package (Directive and Regulation) were officially published in early 2026. [[https://dlrcgroup.com/updates-to-the-eu-pharmaceutical-reform-2026/|HSFKramer]]. This package will fully replace and repeal Directive 2001/83/EC and Regulation (EC) No 726/2004 once it takes full effect (expected around 2028).
  
 ---- ----
algae/pharma_medical.1789335896.txt.gz · Last modified: by robert